Dr. Wahlsten’s practice focuses primarily on U.S. and foreign patent prosecution in a variety of arts, including inventions relating to antibodies and immunotoxins, therapeutic peptides and polypeptides, polymerases, medical and veterinary diagnostic tests, combination medical therapies, therapeutic uses of enzyme inhibition, and supercritical fluids extraction methods/systems. She also assists clients with due diligence reviews as well as patentability, non infringement/invalidity and freedom to operate analyses.
Prior to joining WAVS IP, Dr. Wahlsten was an associate with Townsend and Townsend and Crew. Before starting law school, she worked for two years as a patent agent for a boutique patent prosecution law firm in Palo Alto. As a Postdoctoral Fellow for the National Eye Institute at the National Institutes of Health, Dr. Wahlsten studied cellular mechanisms of autoimmune uveitis. While obtaining her Ph.D. at the University of Minnesota, she designed anticancer immunogens using the superantigen toxic shock syndrome toxin-1 (TSST-1). As an undergraduate researcher at the University of Minnesota, she conducted structural studies of epitopes on the nicotinic acetylcholine receptor targeted by antibodies in patients with the autoimmune disease, myasthenia gravis.
